WO2015099019A1 - ドライアイ治療用点眼剤 - Google Patents
ドライアイ治療用点眼剤 Download PDFInfo
- Publication number
- WO2015099019A1 WO2015099019A1 PCT/JP2014/084261 JP2014084261W WO2015099019A1 WO 2015099019 A1 WO2015099019 A1 WO 2015099019A1 JP 2014084261 W JP2014084261 W JP 2014084261W WO 2015099019 A1 WO2015099019 A1 WO 2015099019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diclofenac
- eye
- cells
- comparative example
- eye drop
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an eye drop for treating dry eye.
- Dry eye is a chronic disease of tears and keratoconjunctival epithelium due to various factors, and is a disease accompanied by eye discomfort and abnormal visual function. Dry eye is a major eye disease affecting 10 to 20% of adults in Europe, the United States, and Japan. The number of patients is increased due to increased use time of display screens, air drying by air conditioning equipment, use of contact lenses, etc. Is increasing.
- Dry eye is caused by a decrease in the amount of tears by decreasing the amount of tears secreted in the lacrimal gland and promoting the evaporation of water due to abnormal lipids and mucins in the tears.
- Decreased tears cause chronic irritation and inflammation of the corneal and conjunctival surfaces, leading to poor patient quality of life.
- steroids have been used to treat inflammation while suppressing inflammation, but safety is not sufficient and there is a tendency to cause side effects.
- Non-steroidal anti-inflammatory drugs such as diclofenac and bromfenac are known as drugs that suppress inflammation instead of steroids.
- Patent Document 1 discloses an anti-inflammatory eye drop containing diclofenac as an active ingredient.
- An object of the present invention is to provide an eye drop for dry eye treatment for suppressing apoptosis due to high osmotic pressure of tears.
- the present invention relates to an eye drop for treating dry eye, which contains diclofenac or a pharmaceutically acceptable salt thereof, and suppresses apoptosis due to high osmotic pressure of tears.
- Diclofenac or a pharmaceutically acceptable salt thereof is preferably contained at a concentration of 0.01 to 0.7% by weight / volume.
- the pharmaceutically acceptable salt of diclofenac is diclofenac sodium.
- polysorbate 80 it is preferable to contain polysorbate 80, borax, or polyvinylpyrrolidone.
- the eye drop for dry eye treatment of the present invention contains diclofenac or a pharmaceutically acceptable salt thereof, thereby suppressing apoptosis due to high osmotic pressure of tears and effectively treating dry eye.
- Example 1 and Comparative Example 1 It is the figure which showed the result of Example 1 and Comparative Example 1. It is the figure which showed the result of Example 1 and Comparative Example 1. It is the figure which showed the result of Example 2 and Comparative Example 2. It is the figure which showed the result of Example 2 and Comparative Example 2. It is the figure which showed the result of Example 3 and Comparative Example 3. It is the figure which showed the result of Example 3 and Comparative Example 3. It is the figure which showed the result of Example 3 and Comparative Example 3. It is the figure which showed the result of Example 3 and Comparative Example 3. It is the figure which showed the result of Example 4 and Comparative Example 4. It is the figure which showed the result of Example 4 and Comparative Example 4. It is the figure which showed the result of Example 4 and Comparative Example 4. It is the figure which showed the result of Example 5 and Comparative Example 5. It is the figure which showed the result of Example 5 and Comparative Example 5.
- Example 5 and Comparative Example 5 It is the figure which showed the result of Example 5 and Comparative Example 5. It is the figure which showed the result of Example 5 and Comparative Example 5. It is the figure which showed the result of Example 5 and Comparative Example 5. It is the figure which showed the result of Example 6 and Comparative Example 6. It is the figure which showed the result of Example 7 and Comparative Example 7. It is the figure which showed the result of Example 8 and Comparative Example 8. It is the figure which showed the result of Example 9 and Comparative Example 9. It is the figure which showed the result of Example 10 and Comparative Example 10.
- the present invention relates to an eye drop for treating dry eye, which contains diclofenac or a pharmaceutically acceptable salt thereof, and suppresses apoptosis due to high osmotic pressure of tears.
- the concentration of diclofenac or a pharmaceutically acceptable salt thereof in the eye drop is preferably 0.01 to 0.7% by weight / volume, preferably 0.05 to 0.5% by weight / volume. Is more preferable. If it is less than 0.01% by weight / volume, the therapeutic effect tends to be weak. When it exceeds 0.7% by weight / volume, the composition tends to be difficult to prepare.
- Examples of the pharmaceutically acceptable salt of diclofenac include diclofenac sodium and diclofenac potassium.
- the pH of the eye drop is preferably 6.0 to 8.5, and more preferably 7.0 to 8.0. If the pH is less than 6.0, there is a tendency that the eye irritation cannot be alleviated, and if the pH exceeds 8.5, the physiological pH is deviated.
- the osmotic pressure ratio of the eye drop is preferably 0.9 to 1.4.
- the osmotic pressure ratio here means the osmotic pressure ratio when compared with physiological saline.
- the eye drop of the present invention may contain a buffer, an isotonic agent, a preservative, a thickener, a solubilizing agent, and a detergent in addition to diclofenac or a pharmaceutically acceptable salt thereof.
- the buffer examples include a combination of phosphoric acid and phosphate, a combination of boric acid and borax, a combination of organic acid and organic acid salt, and the like. Among these, the combination of boric acid and borax is preferable.
- the content of the buffering agent in the eye drop is preferably 0.01 to 10% by weight / volume, more preferably 0.1 to 3% by weight / volume. If it is less than 0.01% by weight / volume, the effects of the present invention tend not to be sufficiently achieved. If it exceeds 10% by weight / volume, eye irritation tends to occur.
- isotonic agents examples include sugars such as glucose, sugar alcohols such as propylene glycol, glycerin, sodium chloride, potassium chloride, mannitol, sorbitol, and xylitol. Among these, sodium chloride and potassium chloride are preferable.
- the content of the tonicity agent in the eye drop is preferably 0.01 to 10% by weight / volume, more preferably 0.1 to 3% by weight / volume.
- reverse soaps such as benzalkonium chloride, benzethonium chloride and chlorhexidine gluconate, parabens such as methylparaben, ethylparaben, propylparaben and butylparaben, alcohols such as chlorobutanol, phenylethyl alcohol and benzyl alcohol Is mentioned. Of these, chlorobutanol is preferred.
- the content of the preservative in the eye drop is preferably 0.001 to 0.5% by weight / volume.
- thickener examples include polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose and the like. Among these, polyvinylpyrrolidone is preferable.
- solubilizer examples include polysorbate 80 (polyoxyethylene sorbitan monooleate, trade name Tween 80), polyoxyethylene oxystearic acid triglyceride, polyethylene glycol, ⁇ or ⁇ -cyclodextrin, and the like. Among these, polysorbate 80 is preferable.
- a calcium salt or a magnesium salt may be included to relieve eye irritation.
- examples of such salts include calcium salts such as calcium pantothenate, calcium chloride, calcium propionate, calcium acetate, calcium lactate and calcium gluconate, or corresponding magnesium salts.
- calcium pantothenate, calcium chloride, and magnesium chloride are preferable.
- the eye drop of the present invention preferably contains polysorbate 80, borax, or polyvinylpyrrolidone among the above-mentioned combined components in order to enhance the effect of suppressing apoptosis due to high osmotic pressure.
- the concentration of polysorbate 80 in the eye drop is preferably 0.1 to 5.0% by weight / volume, and 0.3 to 3.0% by weight / volume. % Is more preferable.
- the concentration of borax in the eye drop is preferably 0.1 to 20.0% by weight / volume, and 0.3 to 15.0% by weight / volume. % Is more preferable.
- the concentration of polyvinylpyrrolidone in the eye drop is preferably 1.0 to 15.0% by weight / volume, and 2.0 to 10.0% by weight / volume. % Is more preferable.
- the eye drop of the present invention relates to an eye drop for dry eye treatment for suppressing apoptosis due to high osmotic pressure of tears among eye drops.
- tear fluid decreases and tear osmotic pressure increases.
- water is discharged from the cells and the cells are exposed to osmotic stress that shrinks.
- cells take in external sodium ions and the like into the cells, and the ionic strength in the cells rises, causing apoptosis.
- ocular tissues in which apoptosis occurs include the cornea, conjunctiva, and lacrimal gland. More specifically, examples of cells in which apoptosis occurs include corneal epithelial cells, conjunctival epithelial cells, and lacrimal gland cells.
- Diclofenac used in the ophthalmic solution of the present invention suppresses apoptosis even under high osmotic pressure conditions of tears by promoting the expression and nuclear translocation of the NFAT5 (Nucleor Factor of Activated T-cells 5) gene.
- the NFAT5 gene product activates the BGT-1 (betaine / GABA transporter-1) gene and the like.
- BGT-1 betaine / GABA transporter-1
- the eye drop of the present invention has the effect of suppressing apoptosis in the cornea, conjunctiva and lacrimal gland due to the high osmotic pressure of tear fluid. More specifically, it has the effect of suppressing apoptosis of corneal epithelial cells, conjunctival epithelial cells, and lacrimal gland cells.
- the amount of eye drops for one eye per time is preferably 1 to 3 drops, and more preferably 1 to 2 drops. Further, when the amount of eye drops for one eye per time is expressed by volume, it is preferably 10 to 300 ⁇ L, more preferably 20 to 200 ⁇ L, and further preferably 30 to 100 ⁇ L.
- the administration interval of the eye drop of the present invention is preferably 1 to 6 times a day, and more preferably 1 to 3 times a day.
- HCE cells human corneal epithelial cells
- the medium was brought to a high osmotic pressure condition with 150 mM NaCl, 280 mM glucose, or 280 mM sorbitol.
- the number of viable cells was measured by the MTT method, and the relative value to the absorbance of the control (isotonic pressure condition) was calculated.
- Example 1 The same operation as in Example 1 was performed except that other non-steroidal anti-inflammatory drug (NSAID) was used instead of diclofenac. The results are shown in FIG. 1A.
- NSAID non-steroidal anti-inflammatory drug
- NSAIDs non-steroidal anti-inflammatory drugs
- Example 2 (Comparative Example 2) The same operation as in Example 2 was performed except that bromfenac was used instead of diclofenac. The results are shown in FIGS. 2A-B.
- diclofenac suppresses apoptosis under high osmotic pressure conditions and further exerts a cell proliferation effect.
- HCE cells were pre-cultured in a medium containing diclofenac for 30 minutes, and further cultured in a medium containing 10 ⁇ M arachidonic acid and diclofenac for 30 minutes.
- arachidonic acid is obtained by adding to induce PGE 2.
- Example 3 (Comparative Example 3) The same operation as in Example 3 was performed except that bromfenac was used instead of diclofenac. The results are shown in FIGS. 3A-C.
- NFAT5 expression enhancement and nuclear translocation promotion effect HCE cells were cultured in a hyperosmotic medium containing diclofenac and 150 mM NaCl for 6 hours (FIGS. 4A and 4C) or 1 hour (FIG. 4B). did.
- Whole cell lysates (FIGS. 4A and 4B) or nuclear extracts (FIG. 4B) were analyzed by immunoblotting using antibodies against NFAT5, actin or lamin B. The intensity of the band of NFAT5 was measured and described as a relative value to the control (isotonic pressure condition not containing diclofenac) (FIGS. 4A and 4B).
- Example 4 (Comparative Example 4) The same operation as in Example 4 was performed except that bromfenac was used instead of diclofenac. The results are shown in FIGS. 4A to 4C.
- diclofenac suppresses apoptosis under high osmotic pressure conditions by improving the expression of NFAT5 and promoting nuclear translocation.
- Example 5 Therapeutic effect of corneal surface injury in rats A lacrimal gland of rats was removed to prepare a dry eye model. 1-5 weeks after lacrimal gland removal, eye drops (5 ⁇ l) containing diclofenac (0.1%, 3.1 mM) were administered three times a day. The amount of tears was measured by a cotton thread test, and the results are shown in FIG. 5A. An image of the cornea stained with fluoroseis is shown in FIG. 5B. The fluorescein score was calculated and shown in FIG. 5C. A section of ocular tissue was prepared 5 weeks after lacrimal gland removal, TUNEL assay and DAPI staining were performed, and the results are shown in FIG. 5D (scale bar is 50 ⁇ m). The number of TUNEL positive cells is shown in FIG. 5E. Numbers are mean ⁇ S. E. M.M. * P ⁇ 0.01 and n. s. Means not significant.
- Example 5 (Comparative Example 5) The same operation as in Example 5 was performed except that bromfenac was used instead of diclofenac. The results are shown in FIGS. 5A to E.
- diclofenac has the effect of treating corneal surface damage in the dry eye model.
- Example 6 The combined HCE cells of diclofenac and polysorbate 80 were pre-cultured for 24 hours in a medium containing 0 ⁇ g / ml, 1 ⁇ g / ml, or 10 ⁇ g / ml polysorbate 80. Furthermore, the cells were cultured for 24 hours in a hyperosmotic medium containing 1 ⁇ M diclofenac, 150 mM NaCl, and polysorbate 80 at the same concentration as the preculture. The number of viable cells was measured by the MTT method, and the results are shown in FIG.
- Example 6 (Comparative Example 6) The same operation as in Example 6 was performed except that diclofenac was not used, and the results are shown in FIG.
- Example 7 Combination of diclofenac and borax HCE cells were pre-cultured for 24 hours in a medium containing 0 ⁇ g / ml, 4 ⁇ g / ml, or 40 ⁇ g / ml borax. Furthermore, the cells were cultured for 24 hours in a hyperosmotic medium containing 1 ⁇ M diclofenac, 150 mM NaCl, and borax at the same concentration as the preculture. The number of viable cells was measured by the MTT method, and the results are shown in FIG.
- Example 7 The same operation as in Example 7 was performed except that diclofenac was not used, and the results are shown in FIG.
- Example 8 Combination HCE cells of diclofenac and popidone were pre-cultured in a medium containing 0 ⁇ g / ml, 10 ⁇ g / ml, or 100 ⁇ g / ml of popidone for 24 hours. Furthermore, the cells were cultured for 24 hours in a hyperosmotic medium containing 1 ⁇ M diclofenac, 150 mM NaCl, and popidone at the same concentration as the preculture. The number of viable cells was measured by the MTT method, and the results are shown in FIG.
- Example 9 Effect of eye drops using borax, boric acid, chlorobutanol, popidone, and polysorbate 80 (hereinafter referred to as combined eye drops) 24 HCE cells in a medium containing 1 ⁇ g / ml combined eye drops Pre-cultured for hours. Furthermore, the cells were cultured for 24 hours in a hyperosmotic medium containing 3 ⁇ M combined eye drops and 150 mM NaCl. The number of viable cells was measured by the MTT method. In addition, the same operation was performed using diclofenac instead of the combined eye drops. The results are shown in FIG.
- the combined ophthalmic solution is an ophthalmic solution having the composition of Formulation Example 3.
- Example 9 The same operation as in Example 9 was performed except that diclofenac or combination eye drops were not used (CTRL), or a buffer solution was used (Vehicle), and the results are shown in FIG.
- diclofenac can be improved by using borax, boric acid, chlorobutanol, popidone, and polysorbate 80 in combination.
- Example 10 The rat lacrimal gland was removed to prepare a dry eye model.
- eye drops (5 ⁇ l) containing diclofenac (0.05%, 1.55 mM, or 0.1%, 3.1 mM) were administered three times a day.
- the tears were stained with fluorescein and the score was calculated. The results are shown in FIG.
- Example 10 (Comparative Example 10) The same operation as in Example 10 was performed except that a buffer solution (Vehicle) was used instead of diclofenac, and the results are shown in FIG.
- diclofenac can treat the corneal surface disorder in the dry eye model.
- Diclofenac sodium 100 mg, NaH 2 PO 4 (anhydrous) 200 mg, Na 2 HPO 4 (anhydrous) 710 mg, sodium chloride 300 mg and ⁇ -cyclodextrin 1000 mg are dissolved in about 80 ml of distilled water, to which 150 mg of pantothenate calcium is added and dissolved. Then, dilute with distilled water to make 100 ml, and filter by sterilization to obtain an eye drop.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
HCE細胞(ヒト角膜上皮細胞)を、ジクロフェナクを含む高浸透圧培地で培養した。培地は、150mMのNaCl、280mMのグルコース、または280mMのソルビトールにより高浸透圧条件とした。生細胞の数をMTT法により測定し、コントロール(等張圧条件)の吸光度に対する相対値を算出した。結果を図1Aおよび図1Bに示した。数値は平均±S.D.(n=3)、*P<0.05;**P<0.01である。
ジクロフェナクに代えて、その他の非ステロイド性抗炎症薬(NSAID)を用いた以外は実施例1と同じ操作を行った。結果を図1Aに示した。
HCE細胞を、ジクロフェナク、および150mMのNaClを含む高浸透圧培地で培養した。6時間培養後のカスパーゼ3様活性を、蛍光ペプチド基質を使用して測定し、結果を図2Aに示した。また、12時間培養後、細胞増殖をBrdU取り込みアッセイにより検討し、その結果をコントロール(等張圧条件)の吸光度に対する相対値として記載した。結果を図2Bに示した。数値は平均±S.D.(n=3)、*P<0.05;**P<0.01である。
ジクロフェナクに代えて、ブロムフェナクを用いた以外は実施例2と同じ操作を行った。結果を図2A~Bに示した。
HCE細胞を、ジクロフェナク、150mMのNaCl、および/またはPGE2を含む高浸透圧培地で24時間培養した。生細胞の数をMTT法により測定し、コントロール(等張圧条件)の吸光度に対する相対値として記載した。結果を図3A、および図3Cに示した。
ジクロフェナクに代えて、ブロムフェナクを用いた以外は実施例3と同じ操作を行った。結果を図3A~Cに示した。
HCE細胞を、ジクロフェナク、および150mMのNaClを含む高浸透圧培地で6時間(図4Aおよび図4C)、または1時間(図4B)培養した。全細胞破砕液(図4Aおよび図4B)、または核抽出液(図4B)を、NFAT5、アクチンまたはラミンBに対する抗体を使用して、イムノブロット法により解析した。NFAT5のバンドの強度を測定し、コントロール(ジクロフェナクを含まない等張圧条件)に対する相対値として記載した(図4Aおよび図4B)。bgt1 mRNAの相対的な発現量をリアルタイムRT-PCRで測定し、アクチンの発現量により基準化した数値を、コントロール(ジクロフェナクを含まない等張圧条件)に対する相対値として記載した(図4C)。数値は平均±S.D.(n=3)、*P<0.05;**P<0.01である。
ジクロフェナクに代えて、ブロムフェナクを用いた以外は実施例4と同じ操作を行った。結果を図4A~Cに示した。
ラットの涙腺を除去し、ドライアイモデルを作製した。涙腺除去の1~5週間後、ジクロフェナク(0.1%、3.1mM)を含む目薬(5μl)を1日3回投与した。涙液量をコットン糸テストにより測定し、結果を図5Aに示した。フルオロセイで染色された角膜の画像を図5Bに示した。フルオレセインのスコアを算出し、図5Cに示した。涙腺除去の5週間後に眼組織の切片を作製し、TUNELアッセイおよびDAPI染色を行い、結果を図5Dに示した(スケールバーは50μm)。TUNEL陽性細胞数を図5Eに示した。数値は平均±S.E.M.、*P<0.01であり、n.s.はnot significantを意味する。
ジクロフェナクに代えて、ブロムフェナクを用いた以外は実施例5と同じ操作を行った。結果を図5A~Eに示した。
HCE細胞を、0μg/ml、1μg/ml、または10μg/mlのポリソルベート80を含む培地で24時間、前培養した。さらに、1μMのジクロフェナク、150mMのNaCl、および前培養と同じ濃度のポリソルベート80を含む高浸透圧培地で24時間培養した。生細胞の数をMTT法により測定し、結果を図6に示した。
ジクロフェナクを用いない以外は、実施例6と同じ操作を行い、結果を図6に示した。
HCE細胞を、0μg/ml、4μg/ml、または40μg/mlのホウ砂を含む培地で24時間、前培養した。さらに、1μMのジクロフェナク、150mMのNaCl、および前培養と同じ濃度のホウ砂を含む高浸透圧培地で24時間培養した。生細胞の数をMTT法により測定し、結果を図7に示した。
ジクロフェナクを用いない以外は、実施例7と同じ操作を行い、結果を図7に示した。
HCE細胞を、0μg/ml、10μg/ml、または100μg/mlのポピドンを含む培地で24時間、前培養した。さらに、1μMのジクロフェナク、150mMのNaCl、および前培養と同じ濃度のポピドンを含む高浸透圧培地で24時間培養した。生細胞の数をMTT法により測定し、結果を図8に示した。
ジクロフェナクを用いない以外は、実施例8と同じ操作を行い、結果を図8に示した。
HCE細胞を、1μg/mlの併用点眼薬を含む培地で24時間、前培養した。さらに、3μMの併用点眼薬、150mMのNaClを含む高浸透圧培地で24時間培養した。生細胞の数をMTT法により測定した。また、併用点眼薬に代えてジクロフェナクを使用して同じ操作を行った。結果を図9に示した。なお、併用点眼液は処方例3の組成の点眼薬である。
ジクロフェナクまたは併用点眼薬を用いない(CTRL)、または緩衝液を用いた(Vehicle)以外は、実施例9と同じ操作を行い、結果を図9に示した。
ラットの涙腺を除去し、ドライアイモデルを作製した。涙腺除去の1週間後、ジクロフェナク(0.05%、1.55mM、または0.1%、3.1mM)を含む目薬(5μl)を1日3回投与した。投与4週間後に涙液をフルオレセインで染色しそのスコアを算出した。結果を図10に示した。
ジクロフェナクに代えて緩衝液を用いた(Vehicle)以外は、実施例10と同じ操作を行い、結果を図10に示した。
ジクロフェナクナトリウム100mg、ホウ砂573mg、ホウ酸868mg、塩化ナトリウム290mg、およびβ-シクロデキストリン100mgを蒸留水約80mlに溶解し、これに乳酸カルシウム150mgを添加して溶解し、蒸留水で希釈して100mlとし、除菌濾過して点眼剤を得る。
ジクロフェナクナトリウム100mg、NaH2PO4(無水)200mg、Na2HPO4(無水)710mg、塩化ナトリウム300mgおよびβ-シクロデキストリン1000mgを蒸留水約80mlに溶解し、これにパントテン酸カルシウム150mgを加えて溶解し、蒸留水で希釈して100mlとし、除菌濾過して点眼剤を得る。
ジクロフェナクナトリウム100mg、ホウ砂450mg、ホウ酸1500mg、クロロブタノール500mg、ポリビニルピロリドンK25 3000mgおよびポリソルベート80(Tween80)500mgを滅菌精製水で溶解して全量100mlとし点眼剤を得る。
Claims (4)
- ジクロフェナクまたはその薬学的に許容可能な塩を含む、涙液の高浸透圧によるアポトーシスを抑制するための、ドライアイ治療用点眼剤。
- ジクロフェナクまたはその薬学的に許容可能な塩を0.01~0.7重量/容量%の濃度で含む、請求項1に記載の点眼剤。
- ジクロフェナクの薬学的に許容可能な塩がジクロフェナクナトリウムである、請求項1または2に記載の点眼剤。
- さらに、ポリソルベート80、ホウ砂、またはポリビニルピロリドンを含む、請求項1~3のいずれかに記載の点眼剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14874918.7A EP3087983A4 (en) | 2013-12-25 | 2014-12-25 | Eye drops for treating dry eye |
US15/105,353 US20160317437A1 (en) | 2013-12-25 | 2014-12-25 | Eye drops for treating dry eye |
JP2015554989A JP6373278B2 (ja) | 2013-12-25 | 2014-12-25 | ドライアイ治療用点眼剤 |
CN201480070890.1A CN105848651B (zh) | 2013-12-25 | 2014-12-25 | 干眼症治疗用滴眼剂 |
KR1020167016868A KR102268536B1 (ko) | 2013-12-25 | 2014-12-25 | 드라이아이 치료용 점안제 |
US15/409,155 US20170189361A1 (en) | 2013-12-25 | 2017-01-18 | Eye drops for treating dry eye |
US16/539,565 US20190365686A1 (en) | 2013-12-25 | 2019-08-13 | Eye drops for treating dry eye |
US16/539,506 US20190365685A1 (en) | 2013-12-25 | 2019-08-13 | Eye drops for treating dry eye |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-267514 | 2013-12-25 | ||
JP2013267514 | 2013-12-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/105,353 A-371-Of-International US20160317437A1 (en) | 2013-12-25 | 2014-12-25 | Eye drops for treating dry eye |
US15/409,155 Continuation US20170189361A1 (en) | 2013-12-25 | 2017-01-18 | Eye drops for treating dry eye |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015099019A1 true WO2015099019A1 (ja) | 2015-07-02 |
Family
ID=53478866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/084261 WO2015099019A1 (ja) | 2013-12-25 | 2014-12-25 | ドライアイ治療用点眼剤 |
Country Status (7)
Country | Link |
---|---|
US (4) | US20160317437A1 (ja) |
EP (1) | EP3087983A4 (ja) |
JP (5) | JP6373278B2 (ja) |
KR (1) | KR102268536B1 (ja) |
CN (2) | CN105848651B (ja) |
TW (1) | TWI670057B (ja) |
WO (1) | WO2015099019A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018083848A (ja) * | 2013-12-25 | 2018-05-31 | 株式会社Lttバイオファーマ | ドライアイ治療用点眼剤 |
JP2020535217A (ja) * | 2017-09-01 | 2020-12-03 | マリー アンド プール エンタープライゼズ,リミテッド | 眼病態を治療するための方法および組成物 |
US11806327B2 (en) | 2018-07-27 | 2023-11-07 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11931331B2 (en) | 2018-07-27 | 2024-03-19 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11969454B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020121277A1 (en) * | 2018-12-14 | 2020-06-18 | Apr Applied Pharma Research, S.A. | Ready to use diclofenac stick packs |
WO2021261474A1 (ja) | 2020-06-24 | 2021-12-30 | 本田技研工業株式会社 | 行動制御装置、行動制御方法、およびプログラム |
KR102487345B1 (ko) * | 2021-02-15 | 2023-01-10 | 동의대학교 산학협력단 | 산골취 추출물을 포함하는 안질환 예방 및 치료용 조성물 |
CN117615756A (zh) * | 2021-07-09 | 2024-02-27 | 广州润尔眼科生物科技有限公司 | 洛索洛芬钠在制备治疗干眼的药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58174310A (ja) | 1982-04-06 | 1983-10-13 | Wakamoto Pharmaceut Co Ltd | 抗炎症点眼剤 |
JP2004315472A (ja) * | 2003-04-18 | 2004-11-11 | Yuuwa Shoji:Kk | 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏 |
JP2010528014A (ja) * | 2007-05-24 | 2010-08-19 | アーシエックス セラピューティックス, インコーポレイテッド | ドライアイを処置するための処方物および方法 |
WO2013047373A1 (ja) * | 2011-09-29 | 2013-04-04 | 千寿製薬株式会社 | 亜塩素酸塩を含有する水性製剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT77445A (hu) * | 1995-01-20 | 1998-04-28 | Wakamoto Pharmaceutical Co. Ltd. | Gyulladásgátló szemcsepp |
JP2003313124A (ja) * | 2002-02-20 | 2003-11-06 | Ophtecs Corp | アポトーシスに起因するドライアイにより生じる眼障害の予防および/または治療のための組成物 |
JPWO2006022291A1 (ja) * | 2004-08-27 | 2008-05-08 | 千寿製薬株式会社 | ドライアイ治療用点眼液 |
AU2007208054A1 (en) * | 2006-01-25 | 2007-08-02 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
CN103040888A (zh) * | 2013-01-13 | 2013-04-17 | 段亚东 | 一种眼外用制剂及其制备方法和用途 |
KR102268536B1 (ko) * | 2013-12-25 | 2021-06-23 | 가부시키가이샤 엘티티 바이오파마 | 드라이아이 치료용 점안제 |
-
2014
- 2014-12-25 KR KR1020167016868A patent/KR102268536B1/ko active IP Right Grant
- 2014-12-25 WO PCT/JP2014/084261 patent/WO2015099019A1/ja active Application Filing
- 2014-12-25 JP JP2015554989A patent/JP6373278B2/ja active Active
- 2014-12-25 EP EP14874918.7A patent/EP3087983A4/en not_active Withdrawn
- 2014-12-25 CN CN201480070890.1A patent/CN105848651B/zh active Active
- 2014-12-25 TW TW103145715A patent/TWI670057B/zh active
- 2014-12-25 US US15/105,353 patent/US20160317437A1/en not_active Abandoned
- 2014-12-25 CN CN201910144481.6A patent/CN109908125A/zh active Pending
-
2017
- 2017-01-18 US US15/409,155 patent/US20170189361A1/en not_active Abandoned
-
2018
- 2018-02-09 JP JP2018021983A patent/JP2018083848A/ja active Pending
-
2019
- 2019-02-13 JP JP2019023457A patent/JP2019070054A/ja active Pending
- 2019-02-13 JP JP2019023458A patent/JP6666487B2/ja active Active
- 2019-08-13 US US16/539,565 patent/US20190365686A1/en not_active Abandoned
- 2019-08-13 US US16/539,506 patent/US20190365685A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081443A patent/JP2020122009A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58174310A (ja) | 1982-04-06 | 1983-10-13 | Wakamoto Pharmaceut Co Ltd | 抗炎症点眼剤 |
JP2004315472A (ja) * | 2003-04-18 | 2004-11-11 | Yuuwa Shoji:Kk | 眼科用製剤、点眼液、人工涙液、コンタクトレンズケアー用品、洗眼液、および眼軟膏 |
JP2010528014A (ja) * | 2007-05-24 | 2010-08-19 | アーシエックス セラピューティックス, インコーポレイテッド | ドライアイを処置するための処方物および方法 |
WO2013047373A1 (ja) * | 2011-09-29 | 2013-04-04 | 千寿製薬株式会社 | 亜塩素酸塩を含有する水性製剤 |
Non-Patent Citations (3)
Title |
---|
PETERSEN A: "POTENTIAL PROTECTIVE EFFECTS OF NSAIDS/ASA IN OXIDATIVELY", OPHTHALMIC RES., vol. 37, ST, 2005, pages 318 - 327, XP008184453, DOI: RESSED HUMAN LENS EPITHELIAL CELLS AND INTACT MOUSE * |
See also references of EP3087983A4 * |
ZHOU: "INCREASED REACTIVE OXYGEN SPECIES CONTRIBUTE TO HIGH", AM. J. PHYSIOL. RENAL. PHYSIOL., vol. 289, NA, 2005, pages F377 - F385, XP055179367, DOI: CL-INDUCED ACTIVATION OF THE OSMOREGULATORY * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018083848A (ja) * | 2013-12-25 | 2018-05-31 | 株式会社Lttバイオファーマ | ドライアイ治療用点眼剤 |
JP2020535217A (ja) * | 2017-09-01 | 2020-12-03 | マリー アンド プール エンタープライゼズ,リミテッド | 眼病態を治療するための方法および組成物 |
US11806327B2 (en) | 2018-07-27 | 2023-11-07 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11931331B2 (en) | 2018-07-27 | 2024-03-19 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11969454B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
Also Published As
Publication number | Publication date |
---|---|
TW201609083A (zh) | 2016-03-16 |
CN109908125A (zh) | 2019-06-21 |
JP2020122009A (ja) | 2020-08-13 |
US20190365685A1 (en) | 2019-12-05 |
US20160317437A1 (en) | 2016-11-03 |
CN105848651B (zh) | 2020-05-08 |
CN105848651A (zh) | 2016-08-10 |
JPWO2015099019A1 (ja) | 2017-03-23 |
TWI670057B (zh) | 2019-09-01 |
US20190365686A1 (en) | 2019-12-05 |
JP2018083848A (ja) | 2018-05-31 |
KR20160096112A (ko) | 2016-08-12 |
JP2019070054A (ja) | 2019-05-09 |
KR102268536B1 (ko) | 2021-06-23 |
EP3087983A4 (en) | 2017-05-10 |
JP2019070055A (ja) | 2019-05-09 |
JP6666487B2 (ja) | 2020-03-13 |
JP6373278B2 (ja) | 2018-08-15 |
US20170189361A1 (en) | 2017-07-06 |
EP3087983A1 (en) | 2016-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6666487B2 (ja) | ドライアイ治療用点眼剤 | |
US9549906B2 (en) | Compositions and methods for treatment of ocular inflammation and/or pain | |
EP2323642B1 (en) | Use of EDTA+tromethamine or of photoenhancers, associated to riboflavin for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders | |
Daull et al. | A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models | |
RU2700927C2 (ru) | Офтальмологическая композиция, содержащая циклоспорин и трегалозу | |
Lazreg et al. | Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications | |
US20070299124A1 (en) | Formulations and methods for treating dry eye | |
JP4987078B2 (ja) | 眼科用組成物 | |
US11878041B2 (en) | Compositions and methods for treating the eye | |
TW201350109A (zh) | 用於降低眼部不適的方法及組成物 | |
US20200188297A1 (en) | LXR Agonist in Topical Ophthalmic Formulation for Treatment of Dry-Eye Disorder | |
US20200171124A1 (en) | Topical compositions for ophthalmic and otic use | |
WO2018043370A1 (ja) | ドライアイ治療剤 | |
US20230338307A1 (en) | Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye | |
RU2792627C2 (ru) | Композиции и способы лечения глаз | |
JP2020172440A (ja) | ドライアイ治療用点眼剤 | |
RU2460517C1 (ru) | Фармацевтическая композиция для комплексного лечения заболеваний глазной поверхности у больных с первичной открытоугольной глаукомой |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14874918 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015554989 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014874918 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014874918 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15105353 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20167016868 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |